Table 2 Summary of safety data
AE | Total population (n = 27) n (%) |
|---|---|
Summary of AEs | |
Any AE | 26 (96) |
Any AE related to study drug | 16 (59) |
Any serious AE | 7 (26) |
Any study drug-related serious AE | 0 |
Death | 2 (7) |
Any AE leading to discontinuation | 2 (7) |
Common AEs (occurring in > 15% of patients) | |
Flushing | 7 (26) |
Diarrhea | 6 (22) |
Infusion-related reaction | 6 (22) |
Nasopharyngitis | 6 (22) |
Urinary tract infection | 6 (22) |
Vomiting | 6 (22) |
Wound | 6 (22) |
Nausea | 5 (19) |
AEs related to study drug in > 2 patients | |
Infusion-related reaction | 6 (22) |
Flushing | 6 (22) |
Diarrhea | 3 (11) |